Heparin Therapeutics will be commencing patient enrolment in 2026 for its Phase 2/3 multi-centre randomised study in patients with severe respiratory infections to prevent ARDS.

Respiratory infections are life-threatening impairment of lung function and oxygenation resulting from direct injury or secondary trauma or infective process and is prevalent in approx. 10% of patients in intensive care units worldwide. The global respiratory tract viral infection market was $62 billion in 2024 with expected growth to ~$120 billion by 2032 (CAGR ~8.5%)

ARDS is a life-threatening impairment of lung function and oxygenation resulting from direct injury or secondary trauma or infective process and is prevalent  in approx. 10% of patients in intensive care units worldwide. The pathology of ARDS shows diffuse alveolar damage resulting in survivors having ongoing functional or physiological sequelae resulting in a high mortality rate with few effective therapeutic modalities (lung protective ventilation). There is no current pharmacological treatment of ARDS. Personalised lung-protective mechanical ventilation reduces mortality and has become the mainstay of treatment in ARDS. Treatment costs are estimated at US $139K after 1 year and US $210K after 2 years and the global device market is expected to reach $19.5 billion by 2029, expanding at a CAGR of 7.3%.

To find out about our other products in development please contact us directly.